Stockreport

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc.  (BRTX) 
NASDAQ:AMEX Investor Relations: biorestorative.com/content/investor-relations
PDF Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized [Read more]